People with fibrodysplasia ossificans progressiva (FOP) now have a third approved treatment. On September 25, the FDA approved Atebrioz (zilurgisertib), a once-daily pill for adults and children 12 and older with FOP, a rare genetic disease in which muscle, tendons, and ligaments gradually turn into bone, according to the FDA announcement.
The approval is based on imaging, not on long-term movement or survival. In the main trial, whole-body CT scans showed that patients taking the drug had less new abnormal bone after 24 weeks than those on placebo.
